 Bluebird Bio Inc NASDAQ:BLUE is in the spotlight today, after the U.S. Food and Drug Administration FDA approved SKYSONA, its gene therapy for the treatment of Cerebral Adrenoleukodystrophy CALD -- a rare neurological disorder found in childrens brains ages three to 12. 